Aaron Goodman: I love this trial

Aaron Goodman shared a post on X/Twitter:

“I love this trial. Less of a drug just as good and less toxic. We need more studies like this in oncology

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.”

Read further.
Source: Aaron Goodman/X

Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.